Biogen has halved the price of its Alzheimer’s drug Aduhelm after sales fell short of expectations because insurers have been reluctant to pay for the treatment.
由於保險公司不願爲治療阿茲海默症的藥物Aduhelm支付費用，百健已將這款銷售低於預期的藥物價格砍半。
您已閱讀9%（212字），剩餘91%（2083字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。